Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FERROUS GLUCONATE

All products: not a benefit

Ferrous Gluconate · DIN 00031097 · 300mg · tablet

Listed, not a benefitHealth Canada: not checked yet (expand to check)
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Health Canada: not checked yet (expand to check)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ferrous Gluconate · DIN 00031097 Manufacturer: Jamp Pharma Corporation; listing date 1996-10-01 Health Canada: not checked yet (expand to check)
Check this DIN again

Ferrous Gluconate: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada: not checked yet (expand to check) · Verify on the e-Formulary ↗ (DIN 00031097)

Source record
DIN 00031097: Ferrous Gluconate Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 200400004; group id 248; item number 0440; lccId None; manufacturer id JPC Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00031097
Interchangeable products
Ferrous Gluconate 300mg · DIN 00545031 · $0.0424
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00031097
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (20:04 Antianemia Drugs) and how they are covered

Matched class: 20:04 Antianemia Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FERROUS SULFATE Some products covered without a code (check the product listing): FERROUS FUMARATE 20:04 Antianemia Drugs

FERROUS FUMARATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 300mg, 60mg/mL · Cap, O/L

FERROUS SULFATE

· 1 products · General benefit · strengths: 75mg/mL · O/L

(IRON) FERRIC CARBOXYMALTOSE

· 1 products · Limited Use, codes 735, 736 · strengths: 50mg/mL · Inj Sol

FERRIC DERISOMALTOSE

· 1 products · Limited Use, codes 610 · strengths: 100mg elemental iron/mL · Inj Sol (Preservative-Free)

IRON SUCROSE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg/mL · Inj Sol-5mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:04
Full class listing Related classes: 20:12 Coagulants and Anti-Coagulants, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Ferrous Gluconate: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026